Rossella Troia
Turin, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.
Journal: Blood cancer journal
Published: March 16, 2021
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
Journal: Annals of hematology
Published: June 08, 2020
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Journal: The Lancet. Haematology
Published: January 29, 2020
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma.
Journal: Frontiers in immunology
Published: July 16, 2018
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.
Journal: Expert opinion on drug metabolism & toxicology
Published: December 14, 2017
Melphalan hydrochloride for the treatment of multiple myeloma.
Journal: Expert opinion on pharmacotherapy
Published: June 30, 2017
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
Journal: European journal of haematology
Published: November 23, 2016
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Journal: Expert opinion on investigational drugs
Published: June 07, 2014
Last Updated: 09/26/2026